These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 17462628

  • 1. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.
    Exp Cell Res; 2007 Jul 01; 313(11):2378-88. PubMed ID: 17462628
    [Abstract] [Full Text] [Related]

  • 2. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR, Almenara JA, Coe S, Grant S.
    Cancer Res; 2007 Oct 01; 67(19):9490-500. PubMed ID: 17909059
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G, Medici MC, Russo GL.
    Anticancer Res; 2008 Oct 01; 28(2A):855-64. PubMed ID: 18507029
    [Abstract] [Full Text] [Related]

  • 6. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A, Farshdousti Hagh M, Alivand MR, Akbari AAM, Shams Asenjan K, Saraei R, Solali S.
    J Cell Physiol; 2018 Oct 15; 233(10):6470-6485. PubMed ID: 29741767
    [Abstract] [Full Text] [Related]

  • 8. Control of apoptosis signaling by Apo2 ligand.
    Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A.
    Recent Prog Horm Res; 1999 Oct 15; 54():225-34. PubMed ID: 10548878
    [Abstract] [Full Text] [Related]

  • 9. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
    Kim K, Fisher MJ, Xu SQ, el-Deiry WS.
    Clin Cancer Res; 2000 Feb 15; 6(2):335-46. PubMed ID: 10690508
    [Abstract] [Full Text] [Related]

  • 10. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
    Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY, Hao C.
    J Cell Mol Med; 2010 Jun 15; 14(6A):1303-17. PubMed ID: 19432816
    [Abstract] [Full Text] [Related]

  • 11. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.
    Leukemia; 2004 Nov 15; 18(11):1780-8. PubMed ID: 15385934
    [Abstract] [Full Text] [Related]

  • 12. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
    Kim CH, Gupta S.
    Int J Oncol; 2000 Jun 15; 16(6):1137-9. PubMed ID: 10811986
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM.
    Int J Cancer; 2002 Jun 01; 99(4):491-504. PubMed ID: 11992538
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.
    Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W.
    J Immunol; 2008 Feb 01; 180(3):1545-55. PubMed ID: 18209050
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.
    Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O.
    Cell Death Differ; 2011 Apr 01; 18(4):700-11. PubMed ID: 21072058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.